InvestorsHub Logo
Followers 834
Posts 119889
Boards Moderated 17
Alias Born 09/05/2002

Re: stuartscott8900 post# 681

Sunday, 11/09/2014 12:33:07 PM

Sunday, November 09, 2014 12:33:07 PM

Post# of 3011
Despite the use of ribavirin, the patient-discontinuation rate in TURQUOISE-2 was very low. Based on the phase-3 data (and ignoring any price differential), I would say ABBV/ENTA have a slight edge over GILD in the cirrhotic segment of the market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News